<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3634">
  <stage>Registered</stage>
  <submitdate>30/08/2012</submitdate>
  <approvaldate>30/08/2012</approvaldate>
  <nctid>NCT01677754</nctid>
  <trial_identification>
    <studytitle>A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy</studytitle>
    <scientifictitle>A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Efficacy and Safety of RO4602522 Added to Background Alzheimer's Disease Therapy in Patients With Moderate Severity Alzheimer's Disease</scientifictitle>
    <utrn />
    <trialacronym>MAyflOwer RoAD</trialacronym>
    <secondaryid>2012-000943-29</secondaryid>
    <secondaryid>BP28248</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Alzheimer's Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Alzheimer's disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Dementias</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - RO4602522
Treatment: drugs - Placebo
Treatment: drugs - Donepezil
Treatment: drugs - Memantine
Treatment: drugs - Rivastigmine
Treatment: drugs - Galantamine

Placebo Comparator: Placebo - Participants will receive placebo as add-on to a background therapy of AChEI (donepezil, rivastigmine, or galantamine) alone or in combination with memantine.

Experimental: RO4602522 1 milligram (mg) - Participants will receive RO4602522 1 mg as add-on to a background therapy of AChEI (donepezil, rivastigmine, or galantamine) alone or in combination with memantine.

Experimental: RO4602522 5 mg - Participants will receive RO4602522 5 mg as add-on to a background therapy of AChEI (donepezil, rivastigmine, or galantamine) alone or in combination with memantine.


Treatment: drugs: RO4602522
Participants will receive RO4602522 orally once daily for 12 months.

Treatment: drugs: Placebo
Participants will receive placebo for RO4602522 orally once daily for 12 months.

Treatment: drugs: Donepezil
Stable dose as background medication

Treatment: drugs: Memantine
Stable dose as background medication in combination with AChEIs

Treatment: drugs: Rivastigmine
Stable dose as background medication

Treatment: drugs: Galantamine
Stable dose as background medication

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Behavior Subscale (ADAS-Cog-11) Score at Month 12</outcome>
      <timepoint>Baseline, Month 12</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants Achieving Response, Defined as an Increase From Baseline of Less Than or Equal to (&lt;=) 4 Points in ADAS-Cog-11</outcome>
      <timepoint>Baseline, Month 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) Scale Score at Month 12</outcome>
      <timepoint>Baseline, Month 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Behavioral Pathology in Alzheimer's Disease Frequency-Weighted Severity Scale (BEHAVE-AD-FW) Score at Month 12</outcome>
      <timepoint>Baseline, Month 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With Worsening in BEHAVE-AD-FW Score</outcome>
      <timepoint>Baseline to Month 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Apathy Evaluation Scale (AES) Score at 12 months</outcome>
      <timepoint>Baseline, Month 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Alzheimer's Disease Cooperative Study Clinician Global Impression of Change (ADCS-CGIC) Scale Score at 12 months</outcome>
      <timepoint>Baseline, Month 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants With Worsening in ADCS-CGIC Score</outcome>
      <timepoint>Baseline to Month 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Global Deterioration Scale (GDS) Score at 12 months</outcome>
      <timepoint>Baseline, Month 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Columbia Suicide Severity Rating Scale (C-SSRS) Score at 12 months</outcome>
      <timepoint>Baseline, Month 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants with Adverse Events</outcome>
      <timepoint>Baseline up to 13 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants with Change in Lens Opacity Grading</outcome>
      <timepoint>Baseline; Months 6, and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants with Abnormal Visual Acuity Test Results</outcome>
      <timepoint>Baseline, Months 6, and 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Michigan Neuropathy Screening Instrument Score</outcome>
      <timepoint>Baseline, Weeks 8, 18, 30, 44, 52, and at the last follow-up visit (12 weeks after last dose, up to 64 weeks)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants Receiving Concomitant Medications</outcome>
      <timepoint>Baseline to 13 Months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Apparent Total Clearance of the Drug From Plasma After Administration of RO4602522</outcome>
      <timepoint>Day -1, pre-dose (0 hour) on Days 14, 28, 84, 168, 252, and 364; 1 to 2 hour post dose on Days 14, 84, 252; 2-4 and 5-6 hours post dose on Days 28, 168, and 364</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Apparent Volume of Distribution at Steady State after Administration of RO4602522</outcome>
      <timepoint>Day -1, pre-dose (0 hour) on Days 14, 28, 84, 168, 252, and 364; 1 to 2 hour post dose on Days 14, 84, 252; 2-4 and 5-6 hours post dose on Days 28, 168, and 364</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Area Under the Plasma Concentration-Time Curve of RO4602522</outcome>
      <timepoint>Day -1, pre-dose (0 hour) on Days 14, 28, 84, 168, 252, and 364; 1 to 2 hour post dose on Days 14, 84, 252; 2-4 and 5-6 hours post dose on Days 28, 168, and 364</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Maximum Plasma Concentration of RO4602522</outcome>
      <timepoint>Day -1, pre-dose (0 hour) on Days 14, 28, 84, 168, 252, and 364; 1 to 2 hour post dose on Days 14, 84, 252; 2-4 and 5-6 hours post dose on Days 28, 168, and 364</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Probable Alzheimer disease, based on the National Institute of Neurological and
             Communicative Disorders and Stroke (NINCDS)/Alzheimer's Disease and Related Disorders
             Association (ADRDA) and Diagnostic and Statistical Manual of Mental Disorders-Fourth
             Edition (DSM-IV-TR) criteria

          -  Mini-Mental State Exam (MMSE) score at screening between 13 and 20, inclusive

          -  Body mass index (BMI) between 18 and 36 kilograms per square meter (kg/m^2)
             (inclusive) at screening

          -  Modified Hachinski Ischemia Score of less than or equal to (&lt;/=) 4

          -  Participants with Cornell Scale for Depression in Dementia (CSDD) scores &lt;/= 13 at
             screening

          -  Receiving treatment with donepezil, rivastigmine, galantamine or any AChEIs in
             combination with memantine for at least 4 months before screening, with their dose and
             formulation stabilized at least 3 months before screening. All formulation and dosages
             are allowed except donezepil 23 mg (alone or in combination)

          -  Females of childbearing potential must have a negative pregnancy test and must agree
             to use effective contraception

          -  Generally healthy and ambulatory or ambulatory-aided (i.e., walker or cane)

          -  Have a reliable caregiver or some other identified responsible person who has frequent
             contact with the participant</inclusivecriteria>
    <inclusiveminage>50</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>90</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Any neurological or psychiatric condition that may occur currently or during the
             course of the study that can impair cognition or functioning that is not associated
             with Alzheimer's disease

          -  Background of mental retardation

          -  Uncontrolled behavioral symptoms incompatible with compliance or evaluability

          -  Alcohol and/or substance abuse or dependence (DSM-IV-TR) in the past 2 years, except
             nicotine use which is allowed. However, smokers treated with nicotine replacement
             therapy or bupropion are excluded

          -  Unstable or poorly controlled hypertension as assessed by the investigator regardless
             of whether or not the participant is taking antihypertensive medications

          -  Unstable or clinically significant cardiovascular disease that could be expected to
             progress, recur, or change during study period to such an extent that it could bias
             the assessment of the clinical or mental status of the participant

          -  Inadequate hepatic, renal or thyroid function

          -  Positive for hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection

          -  Poorly controlled diabetes (glycosylated hemoglobin [HbA1c] greater than or equal to
             [&gt;/=] 9 percent at screening)

          -  Requiring nursing home care. Participants living in assisted living facilities are
             allowed if a reliable caregiver is available (see inclusion criteria)

          -  Current treatment for Alzheimer's disease other than those listed in inclusion
             criteria

          -  Participation at any time in an active Alzheimer's disease vaccine study

          -  Participation in a passive Alzheimer's disease immunization study less than 1 year
             before screening except for a) participants where documented medical history indicate
             that they were randomized to the placebo group in these studies, b) participants
             treated with bapineuzumab where a 6-month exclusion period applies

          -  Recent (&lt;/= 12 weeks) or concomitant use of other Monoamine oxidase inhibitors
             (selective or not) including selegiline or rasagiline

          -  Antidepressant treatments are not allowed except for citalopram up to 20 mg daily,
             escitalopram up to 10 mg daily, paroxetine up to 30 mg daily, sertraline up to 100 mg
             daily and trazodone up to 100 mg daily. If treated with one of these antidepressants,
             the treatment should be present for at least 6 weeks at screening. All other
             antidepressants including other SSRIs, tricyclic antidepressants (TCAs),
             serotonin-norepinephrine reuptake inhibitors (SNRIs), St. John's wort and bupropion
             are excluded

          -  Anti-psychotic use within 4 weeks before screening is not permitted except risperidone
             up to 1.5 mg/day, quetiapine up to 100 milligrams per day (mg/day), olanzapine up to 5
             mg/day, and aripiprazole up to 10 mg daily

          -  Anxiolytics/ hypnotics use is not permitted except for benzodiazepines of short or
             intermediate half-life for anxiety/sleeping disorders. Zolpidem (up to 5 mg/day),
             zopiclone (up to 7.5 mg/day), eszopiclone (up to 2 mg/day), trazodone (up to 50
             mg/day, at bedtime) or zaleplon (up to 5 mg/day) is permitted for insomnia

          -  Anti-Parkinson's agents within 2 weeks before screening are not permitted

          -  Recent (less than 4 weeks prior to screening) or concomitant use of anticonvulsants

          -  Anticholinergics/ antihistaminics within 2 weeks before screening are not permitted,
             except i) if used episodically more than 3 days before the screening cognitive
             measurement, ii) non-sedating antihistaminic medications (without anticholinergic
             effects such as cetirizine) or peripheral anticholinergics without central
             anticholinergic effects (such as, trospium for the treatment of hyperactive bladder),
             which are permitted

          -  Recent (less than 1 week prior to screening) or concomitant use of opioid drugs
             (tramadol, methadone, propoxyphene, or meperidine), cyclobenzaprine and
             dextromethorphan

          -  Concomitant use of sympathomimetic drugs, including sympathomimetics in local
             anesthetics and ephedra supplements</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>24/10/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>542</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>12/06/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,SA,VIC,WA</recruitmentstate>
    <hospital>St Vincent's Hospital Sydney - Darlinghurst</hospital>
    <hospital>Central Coast Neurosciences Research - Erina</hospital>
    <hospital>Southern Neurology - Kogarah</hospital>
    <hospital>Queen Elizabeth Hospital - Woodville</hospital>
    <hospital>Box Hill Hospital; Eastern Clinical Research Unit - Box Hill</hospital>
    <hospital>A.G.Mander Pty Ltd - Geelong</hospital>
    <hospital>Heidelberg Repatriation Hospital - Heidelberg</hospital>
    <hospital>Hollywood Specialist Centre - Nedlands</hospital>
    <hospital>Neurodegenerative Disorders Research - Subiaco</hospital>
    <postcode>2010 - Darlinghurst</postcode>
    <postcode>2250 - Erina</postcode>
    <postcode>2217 - Kogarah</postcode>
    <postcode>5011 - Woodville</postcode>
    <postcode>3128 - Box Hill</postcode>
    <postcode>3220 - Geelong</postcode>
    <postcode>3084 - Heidelberg</postcode>
    <postcode>6009 - Nedlands</postcode>
    <postcode>6008 - Subiaco</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Mississippi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Rhode Island</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Chocen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Kladno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Kutna Hora - Vnitrni Mesto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Prague</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Praha 10</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Praha 4 - Krc</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Praha 5</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Praha 6</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bayonne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bron</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nantes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Pessac</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Reims</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Rennes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Tours</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Vandoeuvre-les-nancy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Villeurbanne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Ellwangen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hannover</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mannheim</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Munchen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Siegen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Emilia-Romagna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lazio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Liguria</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Toscana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Umbria</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Busan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Gyeonggi-do</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Incheon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Bialystok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Gdansk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Katowice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Poznan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Pruszcz Gdanski</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Sopot</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Alicante</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Palencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Sevilla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Vizcaya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Albacete</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Malm√∂</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Stockholm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Crowborough</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Dundee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Glasgow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Isleworth</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Norwich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Plymouth</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Sheffield</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Hoffmann-La Roche</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This Phase II, multicenter, randomized, double-blind, parallel-group, placebo-controlled
      study will evaluate the efficacy and safety of RO4602522 in participants with moderate
      severity Alzheimer's disease. Participants who are taking background therapy of
      acetylcholinesterase inhibitors (AChEI) alone or in combination with memantine for at least 4
      months before screening will be randomized to receive either one of two doses of RO4602522 or
      placebo for 12 months.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01677754</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Trials</name>
      <address>Hoffmann-La Roche</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>